MedTrace Logo

Assessment of Proactive Treatments in Patients With Wet Age-related Macular Degeneration (wAMD) Which Have Never Undergone Treatment of This Particular Disease

NCT03939767 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1563

Last updated 2024-09-20

No results posted yet for this study

Summary

In this observational study researchers want to learn more about changes in visual acuity (clarity of vision) with proactive flexible treatments over time in patients suffering from wet age-related macular degeneration (wAMD) after decision to treat with Aflibercept (Eylea) was made. Wet AMD is an eye disease that progressively destroys the macula, the central portion of the retina, impairing central vision.

Conditions

Interventions

DRUG

Aflibercept (Eylea, BAY86-5321)

As prescribed by the treating physician according to the local label. No IVT aflibercept will be provided due to a nature of observational study.

Sponsors & Collaborators

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-05-12
Primary Completion
2023-07-07
Completion
2023-10-17

Countries

  • Argentina
  • Australia
  • Belgium
  • Canada
  • China
  • Colombia
  • Denmark
  • France
  • Ireland
  • Italy
  • Norway
  • South Korea
  • Spain
  • Sweden
  • Switzerland
  • Thailand
  • United Kingdom

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03939767 on ClinicalTrials.gov